Jump to: navigation, search
Clinical data
  • N/A
Routes of
ATC code
Legal status
Legal status
  • N/A
Pharmacokinetic data
MetabolismN/A -
Elimination half-life17-21 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass531.891 g/mol

WikiDoc Resources for Arbidol


Most recent articles on Arbidol

Most cited articles on Arbidol

Review articles on Arbidol

Articles on Arbidol in N Eng J Med, Lancet, BMJ


Powerpoint slides on Arbidol

Images of Arbidol

Photos of Arbidol

Podcasts & MP3s on Arbidol

Videos on Arbidol

Evidence Based Medicine

Cochrane Collaboration on Arbidol

Bandolier on Arbidol

TRIP on Arbidol

Clinical Trials

Ongoing Trials on Arbidol at Clinical

Trial results on Arbidol

Clinical Trials on Arbidol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Arbidol

NICE Guidance on Arbidol


FDA on Arbidol

CDC on Arbidol


Books on Arbidol


Arbidol in the news

Be alerted to news on Arbidol

News trends on Arbidol


Blogs on Arbidol


Definitions of Arbidol

Patient Resources / Community

Patient resources on Arbidol

Discussion groups on Arbidol

Patient Handouts on Arbidol

Directions to Hospitals Treating Arbidol

Risk calculators and risk factors for Arbidol

Healthcare Provider Resources

Symptoms of Arbidol

Causes & Risk Factors for Arbidol

Diagnostic studies for Arbidol

Treatment of Arbidol

Continuing Medical Education (CME)

CME Programs on Arbidol


Arbidol en Espanol

Arbidol en Francais


Arbidol in the Marketplace

Patents on Arbidol

Experimental / Informatics

List of terms related to Arbidol

Arbidol) is an antiviral drug manufactured by Masterlek in Moscow, Russia.

Chemically, Arbidol features an indole core, functionalized at all positions but one with different substituents.


It is an alternative to Tamiflu (manufactured by Roche Pharmaceuticals) used in the fight against avian influenza. Its antiviral inhibitory effect is still being tested and the current results range from being well accepted in pharmaceutical industry to accepted with a dose of suspicion.

The drug has mainly been tested in Russia[1] and China,[2] and has been shown to be effective against avian flu,[3] suggesting it might be a more affordable and cost-effective drug than the widely used Tamiflu.

There is some evidence that it may be more effective at preventing infections from RNA viruses than from DNA viruses.[4]

It has also been investigated as a candidate drug against hepatitis C.[5]

Mechanism of action

The drug exhibits immunomodulation[6] as well as a specific anti-influenza action against the influenza A and influenza B viruses.

It prevents contact between the virus and host cells and penetration of virus particles into the cell by inhibiting the fusion of the virus lipid shell to the cell membranes. [7]

It possesses interferon inducing action, by stimulating the humoral reaction and the phagocytic function of macrophages.

Dosage forms

The drug is manufactured in the form of tablets and capsules, each tablet containing Arbidol® as its active ingredient (50 mg and 100 mg).

Pharmacokinetics and usage

Side effects in children include sensitization to the drug. No known overdose cases have been reported and allergic reactions are limited to people with hypersensitivity.


  1. Leneva IA, Fediakina IT, Gus'kova TA, Glushkov RG (2005). "[Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A]". Ter. Arkh. (in Russian). 77 (8): 84–8. PMID 16206613.
  2. Wang MZ, Cai BQ, Li LY; et al. (2004). "[Efficacy and safety of arbidol in treatment of naturally acquired influenza]". Zhongguo Yi Xue Ke Xue Yuan Xaue Bao (in Chinese). 26 (3): 289–93. PMID 15266832.
  3. "Works as well as Tamiflu". Retrieved 2008-02-22.
  4. Shi L, Xiong H, He J; et al. (2007). "Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo". Arch. Virol. 152 (8): 1447–55. doi:10.1007/s00705-007-0974-5. PMID 17497238.
  5. Pécheur EI, Lavillette D, Alcaras F; et al. (2007). "Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol". Biochemistry. 46 (20): 6050–9. doi:10.1021/bi700181j. PMID 17455911.
  6. Glushkov RG, Gus'kova TA, Krylova LIu, Nikolaeva IS (1999). "[Mechanisms of arbidole's immunomodulating action]". Vestn. Akad. Med. Nauk SSSR (in Russian) (3): 36–40. PMID 10222830.
  7. Boriskin YS, Pécheur EI, Polyak SJ (2006). "Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection". Virol. J. 3: 56. doi:10.1186/1743-422X-3-56. PMID 16854226.

External links

Influenza Microchapters


Patient Information


Historical Perspective




Differentiating Influenza from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Diagnostic Studies


Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Arbidol On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Arbidol

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Arbidol

CDC on Arbidol

Arbidol in the news

Blogs on Arbidol

Directions to Hospitals Treating Influenza

Risk calculators and risk factors for Arbidol